Skip to Content
Søk Menu

EHA 2024: One of the Most Important for Many Years

Tarec Christoffer El-Galaly, Consultant, Clinical Professor, Department of Hematology, Aarhus University Hospital, presented highlights and Danish perspectives on lymphoma at the Danish Evening at EHA 2024.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Alexander Fuglkjær

Machine Learning Can Reduce Unnecessary Hospitalizations for Cancer Patients

/ Alexander Fuglkjær
AIASH24Lymfom Play the Video 01:23
Ingrid Glimelius

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Ingrid Glimelius
ASH24Lymfom Play the Video 01:46
Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Ingrid Glimelius
ASH24Lymfom Play the Video 03:27
Timothy Fenske

The Majority of Patients with Mantle Cell Lymphoma Probably Don’t Need Auto-Transplant in the Current Treatment Era

/ Timothy S. Fenske
ASH24Lymfom Play the Video 05:17
Mats Jerkeman

There Is Definitely A Need for Novel Treatments for Elderly Patients with Mantle Cell Lymphoma

/ Mats Jerkeman
ASH24Lymfom Play the Video 03:13
Martin Dreyling

ECHO Trial Highlights Acalabrutinib’s Promise in Mantle Cell Lymphoma Treatment

/ Martin Dreyling
ASH24Lymfom Play the Video 03:48

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelomatose

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24
Back to top